Irinotecan and Cisplatin for Lung Cancer Treatment
Author Information
Author(s): Ueoka H, Tanimoto M, Kiura K, Tabata M, Takigawa N, Segawa Y, Takata I, Eguchi K, Okimoto N, Harita S, Kamei H, Shibayama T, Watanabe Y, Hiraki S, Harada M
Primary Institution: Okayama University Medical School
Hypothesis
The study investigates the effectiveness of fractionated administration of irinotecan and cisplatin in treating non-small-cell lung cancer.
Conclusion
The treatment was highly effective for advanced non-small-cell lung cancer with manageable toxicities.
Supporting Evidence
- 20 patients (48%) achieved an objective response.
- The median duration of responses was 8 months.
- The median survival time was 12.5 months.
- The 1-year survival rate was 56.8%.
- Major toxicities included neutropenia and diarrhoea.
Takeaway
Doctors tested two medicines to help people with a type of lung cancer, and many patients got better without too many bad side effects.
Methodology
A phase II study with 44 previously untreated patients receiving irinotecan and cisplatin in a specific schedule.
Limitations
The study had a small sample size and focused only on patients with advanced stages of lung cancer.
Participant Demographics
Patients were previously untreated with stage IIIB or IV non-small-cell lung cancer.
Statistical Information
Confidence Interval
95% confidence interval 32–63%
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website